Pharma BD Deal Intelligence
A reverse-merger shell game: Phoenix Asia hands over 100,000,000 shares valued at $1.0 billion to become ACEA Pharma, giving Scilex's oncology subsidiary a Nasdaq listing while Phoenix pivots from construction to pharma overnight, pending Hart-Scott-Rodino clearance.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Upon closing, Phoenix will be renamed ACEA Pharma, Inc., with its common stock expected to be listed on Nasdaq. ACEA Therapeutics is expected to hold an…
Phoenix to become ACEA Pharma in $1B deal with Scilex subsidiary. The agreement establishes a Cayman Islands holding structure with US listing, granting ACEA's…
Phoenix Asia signed the May 4, 2026 agreement to acquire ACEA Pharma for 100 million new shares valued at $1 billion, marking a strategic shift from…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Scilex Holding announced its subsidiaries ACEA Therapeutics and ACEA Pharma entered a definitive stock acquisition agreement with Phoenix Asia Holdings Limited (Nasdaq: PHOE). Phoenix will issue 100,000,000 newly issued ordinary shares at $10.00 per share (agreed value $1.0 billion) to ACEA Therapeutics in exchange for 100% of ACEA Pharma equity. Upon closing, Phoenix will be renamed ACEA Pharma, Inc. and is expected to continue trading on Nasdaq, giving ACEA Pharma a path to an independent listing separate from Scilex’s U.S. non-opioid pain commercial business. Concurrent with the agreement, Phoenix issued a $20.0M convertible promissory note on May 4, 2026 ($10.00/share conversion, no interest, three-year maturity). The transaction is structured as a reverse merger; closing is expected by the end of 2Q 2026, subject to customary conditions including Hart-Scott-Rodino antitrust clearance and any required Nasdaq approvals. As of this 2026-06-07 review the deal remains Pending — no closing or termination has been reported.
25K US cases/yr · $4.5B Estimated 2024 US EGFR-mutant NSCLC market (Tagrisso US sales proxy)
Non-small cell lung cancer represents ~85% of all lung cancers; EGFR-mutant disease accounts for ~15% of US NSCLC and ~30-50% in East Asian populations. The T790M acquired resistance mutation emerges in ~50-60% of patients progressing on first- or second-generation EGFR-TKIs, sustaining demand for third-generation TKIs that bind T790M-mutant EGFR.
The third-generation EGFR-TKI market is dominated by AstraZeneca's Tagrisso (osimertinib), with secondary entrants including Janssen's Rybrevant/Lazcluze (lazertinib + amivantamab) and several China-originated agents (aumolertinib/Ameile, lazertinib, befotertinib). Abivertinib must differentiate on dosing, CNS penetration, or post-osimertinib resistance to gain US commercial traction.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Phoenix Asia Holdings Limited / ACEA Pharma, Inc. (subsidiary of ACEA Therapeutics / Scilex Holding Company) (this deal) | 2026 | $1.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals